Stocks Gilead Sciences Inc

More

  • This could be the market savior this year Monday, 8 Feb 2016 | 1:08 PM ET
    Traders on the floor of the New York Stock Exchange.

    In a year that looks increasingly dismal for stock market returns, companies may have to come to their own rescue.

  • Stocks set for rough open, again lockstep with oil Monday, 8 Feb 2016 | 7:13 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stock futures were sharply lower, following oil prices this morning, in a continuation of Friday's selloff and a turbulent week.

  • Early movers: CMCSA, GM, MRK, MRVL & more Wednesday, 3 Feb 2016 | 7:58 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Wall Street gets a boost, again driven by oil Wednesday, 3 Feb 2016 | 7:27 AM ET
    Traders work on the floor of the New York Stock Exchange

    U.S. stock futures were higher this morning, following oil prices which were rising in early trading. The Dow dropped nearly 300 points Tuesday as U.S. crude tanked 5.5 percent.

  • Merck& Co. posted an 87 percent drop in fourth-quarter profit compared with last year when the drugmaker had a huge gain from the sale of consumer health business. It beat Wall Street profit forecasts, but came up short on revenue. "This is not business as usual, not in the U.S. and not globally," said analyst Steve Brozak, president of WBB Securities, adding, "Merck gets it."

  • Gilead Sciences Inc. posted a 34 percent increase in fourth-quarter profit, trouncing Wall Street expectations, as sales of its blockbuster hepatitis C drugs soared in Japan and offset lower sales in the U.S. However, Harvoni and Sovaldi sales in the U.S. appear to have begun an expected slowdown, with insurers demanding discounts as high as 45 percent off the...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures fell sharply as declines in oil prices continued to weigh on investor sentiment.

  • NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq stock market:. Xerox Corp., up 52 cents to $9.75. Honeywell International Inc., up $5.23 to $103.20.

  • Business events scheduled for the coming month Friday, 29 Jan 2016 | 2:03 PM ET

    WASHINGTON— Commerce Department releases personal income and spending for December, 8:30 a.m.; Institute for Supply Management releases its manufacturing index for January, 10 a.m.; Commerce Department releases construction spending for December, 10 a.m.. BERLIN— Germany's Federal Labor Agency releases January unemployment figures for Europe's biggest...

  • Business events scheduled for the coming week Friday, 29 Jan 2016 | 1:22 PM ET

    WASHINGTON— Commerce Department releases personal income and spending for December, 8:30 a.m.; Institute for Supply Management releases its manufacturing index for January, 10 a.m.; Commerce Department releases construction spending for December, 10 a.m.. BERLIN— Germany's Federal Labor Agency releases January unemployment figures for Europe's biggest...

  • Gilead names Milligan as new CEO Friday, 29 Jan 2016 | 8:18 AM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

    Gilead Sciences on Friday that John Milligan, currently president and chief operating officer, will be promoted to CEO and appointed to the board of directors.

  • Gilead may face legal action for pricing: Mass. AG Wednesday, 27 Jan 2016 | 2:45 PM ET
    The headquarters of Gilead Sciences in Foster City, Calif.

    Massachusetts AG Maura Healey said the costs of two drugs "may constitute an unfair trade practice in violation of Massachusetts law."

  • Credit Suisse: Sell FANG, other crowded stocks Monday, 25 Jan 2016 | 3:57 PM ET
    Traders work on the floor of the New York Stock Exchange.

    A group of widely owned stocks may be at risk of taking a hit as investors unwind their exposure to equities amid increased volatility in 2016.

  • Kaiser Permanente CEO: Can't rationalize drug costs Friday, 22 Jan 2016 | 6:46 AM ET
    Bernard Tyson, Kaiser Permanente

    Kaiser Permanente CEO Bernard Tyson says a free market for prescription drugs doesn't exist in the United States.

  • Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...

  • Poor 2016 price action sets some stocks up for pop Wednesday, 6 Jan 2016 | 5:00 AM ET
    Worried NYSE traders

    A recent sell-off pushed a group of stocks further into oversold territory, setting them up for a potential rebound, should history be any guide.

  • *First Solar up after Goldman upgrades stock to buy. After weak Chinese economic data drove stocks down sharply on Monday, the People's Bank of China on Tuesday injected $20 billion into the financial system in a bid to help its markets. Wal Mart Stores Inc shares, up 2.4 percent at $62.92, helped to lift both the Dow and S&P 500, though Monday's big selloff and...

  • *First Solar up after Goldman upgrades stock to buy. In a bid to stabilize its markets, the People's Bank of China on Tuesday injected $20 billion into the financial system. Gilead Sciences Inc rose 1.7 percent to $99.64, helping to lift the S&P 500, after its experimental hepatitis B drug was found safer than, yet as effective, as its approved treatment Viread.

  • Jan 5- Gilead Sciences Inc said its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread, in two late-stage studies. Gilead's shares rose 1 percent to $99 in premarket trading. The company plans to seek regulatory approval for TAF in the United States and Europe in the first quarter of 2016..

  • Gilead's hep B drug succeeds in late-stage trials Tuesday, 5 Jan 2016 | 8:53 AM ET

    Jan 5- Gilead Sciences Inc said its once-daily experimental hepatitis B drug was found to be as effective as its approved drug, Viread, in two late-stage studies. The drug, tenofovir alafenamide, or TAF, also showed improved renal and bone safety compared with Viread, Gilead said on Tuesday. Gilead plans to submit regulatory applications for TAF in the United...